IRIS
Narcisi, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.517
NA - Nord America 2.796
SA - Sud America 1.074
EU - Europa 632
AF - Africa 114
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
AN - Antartide 1
Totale 8.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.647
SG - Singapore 2.021
BR - Brasile 852
CN - Cina 580
VN - Vietnam 542
IT - Italia 111
AR - Argentina 97
HK - Hong Kong 92
FI - Finlandia 73
CA - Canada 68
IE - Irlanda 66
IN - India 60
FR - Francia 56
GB - Regno Unito 55
DE - Germania 51
MX - Messico 46
EC - Ecuador 45
ID - Indonesia 35
RU - Federazione Russa 33
BD - Bangladesh 30
NL - Olanda 29
NG - Nigeria 27
ZA - Sudafrica 27
SE - Svezia 24
CO - Colombia 23
PL - Polonia 22
BE - Belgio 21
ES - Italia 20
IQ - Iraq 20
UA - Ucraina 20
PK - Pakistan 19
JP - Giappone 18
TR - Turchia 17
MA - Marocco 14
PY - Paraguay 14
VE - Venezuela 13
MY - Malesia 11
TN - Tunisia 11
CL - Cile 9
PE - Perù 9
DZ - Algeria 8
KE - Kenya 8
HN - Honduras 7
NP - Nepal 7
EG - Egitto 6
PH - Filippine 6
UZ - Uzbekistan 6
XK - ???statistics.table.value.countryCode.XK??? 6
AT - Austria 5
DO - Repubblica Dominicana 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LT - Lituania 5
SA - Arabia Saudita 5
UY - Uruguay 5
AL - Albania 4
BO - Bolivia 4
CZ - Repubblica Ceca 4
ET - Etiopia 4
IL - Israele 4
LV - Lettonia 4
OM - Oman 4
PS - Palestinian Territory 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
AZ - Azerbaigian 3
BH - Bahrain 3
CH - Svizzera 3
CR - Costa Rica 3
EE - Estonia 3
GE - Georgia 3
HU - Ungheria 3
JM - Giamaica 3
NI - Nicaragua 3
PA - Panama 3
RO - Romania 3
SR - Suriname 3
TT - Trinidad e Tobago 3
BG - Bulgaria 2
BY - Bielorussia 2
GR - Grecia 2
GT - Guatemala 2
KW - Kuwait 2
LB - Libano 2
LY - Libia 2
MT - Malta 2
PR - Porto Rico 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
DK - Danimarca 1
GA - Gabon 1
GN - Guinea 1
GP - Guadalupe 1
Totale 8.132
Salva come PNG Salva come JPEG
Città #
Singapore 659
Ashburn 381
San Jose 345
Chandler 245
Shanghai 205
Ho Chi Minh City 188
Dallas 179
The Dalles 167
Beijing 165
Hanoi 100
New York 92
Hong Kong 90
Boardman 89
Wilmington 86
Los Angeles 78
Helsinki 73
São Paulo 69
Santa Clara 66
Dublin 65
San Mateo 45
Milan 39
Ann Arbor 34
Lawrence 34
Princeton 34
Haiphong 31
Benin City 27
Buffalo 26
Da Nang 26
Paris 26
Rio de Janeiro 26
Brooklyn 23
Brussels 21
Mexico City 21
Phoenix 20
Orem 18
Belo Horizonte 17
Guayaquil 17
Tokyo 17
Hải Dương 16
London 16
Montreal 16
Seattle 16
Warsaw 16
Amsterdam 15
Can Tho 15
Johannesburg 15
Leawood 14
Toronto 14
Chicago 13
Assago 12
Buenos Aires 12
Chennai 12
Curitiba 12
Quito 12
Salvador 12
Charlotte 11
Frankfurt am Main 11
Brasília 10
Council Bluffs 10
Fairfield 10
Ninh Bình 10
Atlanta 9
Boston 9
Dronten 8
Falkenstein 8
Jakarta 8
Mumbai 8
Nairobi 8
Poplar 8
Porto Alegre 8
San Francisco 8
Sorocaba 8
São Bernardo do Campo 8
Thái Bình 8
Bauru 7
Campinas 7
Dhaka 7
Goiânia 7
Houston 7
Lima 7
Munich 7
Phủ Lý 7
Recife 7
Teresina 7
Tây Ninh 7
Uberlândia 7
Anápolis 6
Baghdad 6
Biên Hòa 6
Bắc Giang 6
Caracas 6
Ha Long 6
Istanbul 6
New Delhi 6
Osasco 6
Ottawa 6
Sumaré 6
Tashkent 6
Tunis 6
Woodbridge 6
Totale 4.418
Salva come PNG Salva come JPEG
Nome #
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 202
Chronic Hand Eczema (CHE): A Narrative Review 112
Brodalumab: a new way to inhibit IL-17 in psoriasis 112
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 98
Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis) 98
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 92
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 90
Programmed cell death in the skin 89
Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey 89
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 88
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) 85
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 83
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 83
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan 81
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response 80
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 78
S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis 77
Long-term safety and efficacy of adalimumab in psoriasis: a multicentric study focused on infections (connecting study) 77
Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders 76
25-Hydroxyvitamin D serum levels and melanoma risk: a case-control study and evidence synthesis of clinical epidemiological studies 74
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 72
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? 71
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks 69
Measuring psoriatic disease in clinical practice. An expert opinion position paper 69
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) 67
Long-term safety of etanercept in psoriasis: Retrospective study focused on infections 67
noveaux horizon therapeutiques pour le prurit dermatologique au delà de la dermatite atopique: role de i-modulia 67
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab 66
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 66
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital 65
Diagnostic imaging: Listening in to skin disease 65
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab 64
Noninvasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal Microscopy 64
Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis 63
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report 63
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 62
TP63 and TP73 in cancer, an unresolved "family" puzzle of complexity, redundancy and hierarchy. 62
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 61
Suicide risk and psychiatric comorbidity in patients with psoriasis 58
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis) 56
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis) 55
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) 55
An 18-year follow-up of a case of D-penicillamine-induced Elastosis perforans serpiginosa 55
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study 54
Potential Role of Leptin in JAK2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study 53
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 53
Daily Patient's Relief From Pruritus and Sleep Disturbance Over One-Month Treatment with Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Multicenter Prospective Study 53
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 52
Urticarial rash in autoinflammatory syndromes 52
Bullous vasculitis associated with Streptococcus pyogenes sepsis 51
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis) 51
Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction 50
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab 49
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 49
Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis 48
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review 48
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study 48
What Can IBD Specialists Learn from IL-23 Trials in Dermatology? 47
Update on the Management of Pediatric Psoriasis: An Italian Consensus 46
An unusual case of annular bollous eruption of the inguinal folds 46
Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy 46
A case of lichen amyloidosus treated with acitretin 46
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study 45
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study 45
Fingertip dermatitis: a spy for psoriasis 45
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience 44
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study 44
Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104-week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS) 44
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 44
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 44
Disseminated Superficial Porokeratosis with Dermal Amyloid Deposits 43
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis) 43
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis 43
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment 43
Allergy to nickel: first results on patients administered with an oral hyposensitization therapy 43
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study 43
A Case of Ketron-Goodman Disease 43
Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) 43
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study 43
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience 42
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 42
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? 42
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel 41
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus 41
A case of periocular contact dermatitis caused by cypress allergy 40
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals 40
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience 40
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma 40
Atypical facial pustular folliculitis by Klebsiella pneumoniae: a case report 40
Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report 40
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination 39
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study 39
Autoreactivity to self-antigens LL37 and ADAMTSL5 influences the clinical response to risankizumab in psoriatic patients 39
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis 39
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) 39
Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study 39
An updated safety review of Hidradenitis Suppurativa treatment options 38
Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study 38
Angiomatoid lesions (leukocytoclastic vasculitis) as paraneoplastic manifestations of multiple myeloma IgA λ 37
A case of cutaneous large B-cell lymphoma of the legs appearing as chronic venous ulceration 37
Totale 5.842
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.963
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 0 0 0 0 0 0 0 0 17
2021/2022154 2 0 5 31 1 0 9 21 13 17 46 9
2022/2023609 82 48 46 87 59 45 1 48 99 47 41 6
2023/2024623 25 49 126 27 15 60 60 66 16 20 64 95
2024/20251.333 15 22 19 18 8 111 94 68 170 242 215 351
2025/20265.445 689 407 537 854 297 228 1.079 319 305 301 214 215
Totale 8.322